Literature DB >> 17109856

Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice.

Anna Wesołowska1, Ewa Tatarczyńska, Agnieszka Nikiforuk, Ewa Chojnacka-Wójcik.   

Abstract

Using the forced swimming test in mice, we examined the effect of the following antidepressants: citalopram, imipramine, desipramine and moclobemide (which are characterized by different mechanisms of action), administered in combination with the selective 5-HT7 receptor antagonist (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]-pyrrolidine (SB 269970). All those drugs were given in doses which did not shorten the immobility time of mice. Citalopram (1.25 mg/kg), imipramine (10 mg/kg), desipramine (5 mg/kg) or moclobemide (10 mg/kg) administered jointly with SB 269970 (5 mg/kg), produced a significant antidepressant-like effect. None of the compounds studied, given alone or in combination, increased the spontaneous locomotor activity of mice. The obtained results indicate that blockade of 5-HT7 receptors may facilitate the anti-immobility effect of antidepressants in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109856     DOI: 10.1016/j.ejphar.2006.10.001

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

Review 2.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

3.  Lack of persistent effects of ketamine in rodent models of depression.

Authors:  Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal:  Psychopharmacology (Berl)       Date:  2008-05-07       Impact factor: 4.530

Review 4.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

5.  Vortioxetine (brintellix): a new serotonergic antidepressant.

Authors:  Andrew D'Agostino; Clayton D English; Jose A Rey
Journal:  P T       Date:  2015-01

6.  Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.

Authors:  Minako Tajiri; Atsuko Hayata-Takano; Kaoru Seiriki; Katsuya Ogata; Keisuke Hazama; Norihito Shintani; Akemichi Baba; Hitoshi Hashimoto
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

7.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

Review 8.  The 5-HT7 receptor and disorders of the nervous system: an overview.

Authors:  Peter B Hedlund
Journal:  Psychopharmacology (Berl)       Date:  2009-08-01       Impact factor: 4.530

Review 9.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice.

Authors:  Meredith A Fox; Catherine L Jensen; Helen T French; Alison R Stein; Su-Jan Huang; Teresa J Tolliver; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2008-08-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.